HLA-A and myeloid sarcoma: The product of HLA-A*30:02 allele, which is more frequent in Bahrain MS patients compared with in control subjects [25], is capable of binding the MBP peptide GYGGRASDY, which is released by proteasomes purified from cells exposed to IFNγ two orders of magnitude more efficiently than HEK293T proteasomes (Figure 5b).